These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 27033341)

  • 1. Effect of flecainide on suppression of ventricular fibrillation in a patient with early repolarization syndrome.
    Ahn J; Roh SY; Lee DI; Shim J; Choi JI; Kim YH
    Heart Rhythm; 2016 Aug; 13(8):1724-8. PubMed ID: 27033341
    [No Abstract]   [Full Text] [Related]  

  • 2. Reply to the Editor- Effect of Flecainide on Suppression of Ventricular Fibrillation in a Patient With Early Repolarization Syndrome.
    Ahn J; Kim YH
    Heart Rhythm; 2016 Sep; 13(9):e291. PubMed ID: 27320516
    [No Abstract]   [Full Text] [Related]  

  • 3. To the Editor-Flecainide and ventricular fibrillation in patients with early repolarization syndrome.
    Mahida S; Derval N
    Heart Rhythm; 2016 Sep; 13(9):e291. PubMed ID: 27343857
    [No Abstract]   [Full Text] [Related]  

  • 4. [Study of flecainide in the treatment of ventricular arrhythmia].
    Hug C; Koliopoulos N; Tardy C; Errera J; Puech P
    Ann Cardiol Angeiol (Paris); 1983 May; 32(3):161-4. PubMed ID: 6193751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Flecainide acetate for the treatment of atrial and ventricular arrhythmias.
    Apostolakis S; Oeff M; Tebbe U; Fabritz L; Breithardt G; Kirchhof P
    Expert Opin Pharmacother; 2013 Feb; 14(3):347-57. PubMed ID: 23294160
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduction of dispersion of repolarization and prolongation of postrepolarization refractoriness explain the antiarrhythmic effects of quinidine in a model of short QT syndrome.
    Milberg P; Tegelkamp R; Osada N; Schimpf R; Wolpert C; Breithardt G; Borggrefe M; Eckardt L
    J Cardiovasc Electrophysiol; 2007 Jun; 18(6):658-64. PubMed ID: 17521304
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Shock-resistant ventricular fibrillation.
    Ghosh J; McGuire MA; Kilborn MJ; Singarayar S; Medi C; Sy RW
    Int J Cardiol; 2014 Jun; 174(2):e26-8. PubMed ID: 24726354
    [No Abstract]   [Full Text] [Related]  

  • 8. [Propafenone and flecainide in the therapy of ventricular arrhythmias].
    Paperini L; Davini A; Lattanzi F; Topi A; Reisenhofer B; Squarcini G; Paci A; Topi PL
    Minerva Cardioangiol; 1995 Oct; 43(10):449-57. PubMed ID: 8819814
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ventricular arrhythmias: risk stratification and approach to therapy after the Cardiac Arrhythmia Suppression Trial (CAST).
    Prystowsky EN; Katz A; Knilans TK
    Pacing Clin Electrophysiol; 1990 Nov; 13(11 Pt 2):1480-7. PubMed ID: 1702527
    [No Abstract]   [Full Text] [Related]  

  • 10. Flecainide: a new agent for the treatment of ventricular arrhythmias.
    Grubb BP; Tilley-Gray B
    Am J Med Sci; 1986 Sep; 292(3):160-3. PubMed ID: 3529958
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Flecainide and anti-arrhythmia therapy].
    Croce L; Romano S; Pozzoni L; Lomuscio A
    Minerva Med; 1988 Mar; 79(3):229-34. PubMed ID: 3129677
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Differential indications for anti-arrhythmia therapy].
    Manz M; Wagner WL; Lüderitz B
    Internist (Berl); 1987 Mar; 28(3):182-9. PubMed ID: 2438248
    [No Abstract]   [Full Text] [Related]  

  • 13. Oral flecainide for suppression of ventricular arrhythmias.
    Vanhaleweyk G; Balakumaran K; Lubsen J; Roelandt J; Hugenholtz PG
    Cardiology; 1984; 71(1):30-9. PubMed ID: 6722846
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Combination anti-arrhythmia therapy].
    Manz M; Jung W; Lüderitz B
    Internist (Berl); 1993 May; 34(5):444-51. PubMed ID: 7685329
    [No Abstract]   [Full Text] [Related]  

  • 15. [Tactics of treatment of patients with arrhythmia].
    Glezer MG; Orlov LL
    Klin Med (Mosk); 1995; 73(4):13-7. PubMed ID: 7474808
    [No Abstract]   [Full Text] [Related]  

  • 16. Relation between activation sequence fluctuation and arrhythmogenicity in sodium-channel blockades.
    Watanabe T; Yamaki M; Kubota I; Tachibana H; Tomoike H
    Am J Physiol; 1999 Sep; 277(3):H971-7. PubMed ID: 10484418
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [What is safe in the therapy of tachycardic heart arrhythmias?].
    Wehr M; Noll B; Krappe J
    Internist (Berl); 1985 Dec; 26(12):741-9. PubMed ID: 2417980
    [No Abstract]   [Full Text] [Related]  

  • 18. Flecainide attenuates rate adaptation of ventricular repolarization in guinea-pig heart.
    Osadchii OE
    Scand Cardiovasc J; 2016; 50(1):28-35. PubMed ID: 26402340
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Suppression of resistant ventricular arrhythmias by twice daily dosing with flecainide.
    Duff HJ; Roden DM; Maffucci RJ; Vesper BS; Conard GJ; Higgins SB; Oates JA; Smith RF; Woosley RL
    Am J Cardiol; 1981 Dec; 48(6):1133-40. PubMed ID: 7304461
    [No Abstract]   [Full Text] [Related]  

  • 20. Short QT syndrome: pharmacological treatment.
    Gaita F; Giustetto C; Bianchi F; Schimpf R; Haissaguerre M; Calò L; Brugada R; Antzelevitch C; Borggrefe M; Wolpert C
    J Am Coll Cardiol; 2004 Apr; 43(8):1494-9. PubMed ID: 15093889
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.